Tirzepatide has emerged as a groundbreaking therapy for type 2 diabetes, offering promising outcomes. However, the expense of this innovative drug and its availability have become key concerns for patients and healthcare providers. While tirzepatide has been approved by regulatory agencies, its expensive nature presents a significant challenge to